Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone

References

• Jaffe ES, Harris NL, Stein H, et al., editors. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissue. Lyon: IARC Press; 2001.
   Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007;109;1857–1861.
   PubMed Web of Science ®Google Scholar
• Reichard P, Estborn B. Utilization of deoxyribosides in the synthesis of polynucleotides. J Biol Chem 1951;188:839–846.
   PubMed Web of Science ®Google Scholar
• Kit S. Viral-associated and induced enzymes. Phamacal Therapeut 1979;4:501–585.
   Web of Science ®Google Scholar
• Bello LJ. Regulation of thymidine kinase synthesis in human cells. Exp Cell Res 1974;89:263–274.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Horming SJ, Coiffeir B, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999;17:1244–1253.
   PubMed Web of Science ®Google Scholar
• Torizumi K, Aibata H, Yamada R, et al. A study on the measurement of serum thymidine kinase and its clinical significance in hematological neoplastic disorders. Kaku Igaku 1988;26:561–567.
   Google Scholar
• Gronowitz JS, Kallamder CFR, Diderholm H, et al. Application of an in vitro assay for serum thymidine kinase: results on viral disease and malignancies in humans. Int J Cancer 1984;33:5–12.
   PubMed Web of Science ®Google Scholar
• Ellims PH, Eng Gan T, Medley G, et al. Prognostic relevance of thymidine kinase in adult non-Hodgkin's lymphoma. Blood 1981;58:926–930.
   PubMed Web of Science ®Google Scholar
• Kallander CF, Simmonsson B, Hagberg H, et al. Serum deoxythymidine kinase gives prognostic information in chronic lymphoblastic leukemia. Cancer 1984;54:2450–2455.
   PubMed Web of Science ®Google Scholar
• Martinsson U, Glimelius B, Hagberg H, et al. Primarily asymptomatic low grade non-Hodgkin's lymphomas: prediction of symptom-free survival and total survival. Eur J Haematol 1989;43: 332–338.
   PubMed Web of Science ®Google Scholar
• Kallander CF, Simonsson B, Gronowitz JS, et al. Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphoblastic leukemia. Eur J Haematol 1987;38:331–337.
   PubMed Web of Science ®Google Scholar
• Pan ZL, Ji XY, Shi YM, et al. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients. J Cancer Res Clin Oncol 2010;136: 1193–1199.
   PubMed Web of Science ®Google Scholar
• Suki S, Swan F Jr, Tucker S, et al. Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymphoma 1995;18:87–92.
   PubMed Web of Science ®Google Scholar
• Procházka V, Faber E, Raida L, et al. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk Lymphoma 2012;53:1306–1310.
   PubMed Web of Science ®Google Scholar
• Suzuki K, Terui Y, Nakano K, et al. High thymidine kinase activity is a strong predictive factor for poor prognosis in PTCLs treated by CHOP. Leuk Lymphoma 2012;53:849–854.
   PubMed Web of Science ®Google Scholar
• Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of dilluse large B-cell lymphoma (LNH03-2B): an open-label randomized phase 3 trial. Lancet 2011;378:1858–1867.
   PubMed Web of Science ®Google Scholar
• Gang AO, Strom C, Perersen M, et al. R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Dannish Lymoma Group. Ann Oncol 2012;23:147–153.
   Google Scholar
• Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997;336:1290–1298.
   PubMed Web of Science ®Google Scholar
• Milipied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–1295.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Unger JM, Cook J, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP± R for eight cycles to CHOP± R six cycles followed by autotransplant for patients with high-intermediate (H-I) or high IPI grade diffuse aggressive non-Hodgkin's lymphoma (NHL). J Clin Oncol 2011;29(Suppl.): Abstract 8001.
   Google Scholar
• Corazzelli G, Frigeri F, Russo F, et al. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cyrtarabine in adult Burkitt lymphoma and “unclassifiable” highly aggressive B-cell lymphoma. Br J Haematol 2012;156:234–244.
   PubMed Web of Science ®Google Scholar
• Maruyama D, Watanabe T, Maeshima AM, et al. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol 2010;92:732–743.
   PubMed Web of Science ®Google Scholar
• Lin P, Dickason TJ, Fayad LE, et al. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer 2012;118:1366–1373.
   Google Scholar
• El Gnaoui T, Dupuis J, Belhadj K, et al. Ritaxumab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol 2007;18:1363–1368.
   PubMed Web of Science ®Google Scholar
• Sirohi B, Cunningham D, Norman A, et al. Gemcitabine, cisplatin and methylpredonisolone (GEM-P) with or without rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL). Hematology 2007;12:149–153.
   PubMed Web of Science ®Google Scholar
• Robertson MJ, Kahl BS, Vose JM, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25: 1741–1746.
   PubMed Web of Science ®Google Scholar
• Smith SM, van Besien K, Karrison T, et al. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: the University of Chicago phase II consortium. J Clin Oncol 2010;28: 4740–4746.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetnham J, et al. Inhibition of SyK with fostamatinib disodium has significant clinical activity in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Blood 2010;115:2578–2585.
   PubMed Web of Science ®Google Scholar
• Ruan J, Martin P, Furman PR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011;29:690–697.
   PubMed Web of Science ®Google Scholar